Physician profile
David C Bartels
NPI 1245492768
$10,730.95
in general payments reported to CMS, 2019-2025
68 companies · $1,697 in 2025
The $1,697 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,815 · 2020: $582 · 2021: $517 · 2022: $1,125 · 2023: $1,902 · 2024: $2,092 · 2025: $1,697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,576 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,576.22 |
| Education | $114.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $977.30 | 2019-2025 | |
| Pfizer INC. | $924.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $740.55 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $671.01 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $620.93 | 2019-2025 | Reblozyl, Opdualag |
| Seagen INC. | $478.67 | 2019-2023 | Adcetris, Tukysa |
| Amgen INC. | $452.62 | 2019-2024 | Krystexxa, Tepezza, Uplizna |
| Astrazeneca Pharmaceuticals Lp | $420.28 | 2019-2025 | Imfinzi, Lynparza, Tagrisso |
| Janssen Biotech, INC. | $404.06 | 2019-2025 | Tecvayli, Erleada, Talvey |
| Abbvie INC. | $360.13 | 2019-2025 | Venclexta |
| Eisai INC. | $266.33 | 2019-2025 | |
| Genentech USA, INC. | $262.91 | 2019-2025 | Polivy, Perjeta, Alecensa |
| Lilly USA, LLC | $229.27 | 2019-2024 | Verzenio, Taltz, Olumiant |
| Glaxosmithkline, LLC. | $227.39 | 2020-2025 | Ojjaara, Shingrix, Jemperli |
| Array Biopharma INC | $207.87 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bartels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.